Loading patent…
AssigneeMitoPower LLC
InventorsG. Mani Subramanian, Gautham Tumkur Pranesh, Gangadhara Ganapati, Nikhill Saji Zachariah, K.S. Ajay Kumar
Estimating the term…
The disclosure relates to in vivo and ex vivo uses of dihydronicotinamide riboside (NRH), dihydronicotinic acid riboside (NARH) and reduced derivatives thereof to treat immune-related disorders (e.g., systemic inflammatory response syndrome and sepsis), kidney disorders (e.g., acute kidney injury and hepatorenal syndrome [HRS]), liver disorders (e.g., acute liver failure and HRS), hemolytic disorders (e.g., hemolysis and hemolytic anemia), and disorders and conditions associated with oxidative stress, damage or injury (e.g., methemoglobinemia and anemia). NRH, NARH and reduced derivatives thereof can be used in vivo or ex vivo alone or in combination with one or more additional therapeutic agents, such as an anti-inflammatory agent or/and an antioxidant.
A method of treating an immune-related disorder, a kidney disorder, a liver disorder, a hemolytic disorder, or a disorder or condition associated with oxidative stress, damage or injury, comprising administering to a subject in need thereof a therapeutically effective amount of dihydronicotinamide riboside (NRH), dihydronicotinic acid riboside (NARH) or a reduced derivative thereof, or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, polymorph or stereoisomer thereof.
A pharmaceutical composition comprising one or more pharmaceutically acceptable excipients or carriers, and dihydronicotinamide riboside (NRH), dihydronicotinic acid riboside (NARH) or a reduced derivative thereof, or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, polymorph or stereoisomer thereof, wherein the composition is in a lyophilized (freeze-dried) form.
Dependencies are inferred from the claim text.